logo
Plus   Neg
Share
Email

Sanofi: Libtayo Shows Clinically-Meaningful And Durable Responses In Skin Cancer

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced topline data from a pivotal, single-arm, open-label trial for the PD-1 inhibitor Libtayo in patients with advanced basal cell carcinoma who had progressed on or were intolerant to prior hedgehog pathway inhibitor therapy.

Libtayo demonstrated clinically meaningful and durable responses in Second-line Advanced Basal Cell Carcinoma. Regeneron and Sanofi plan regulatory submissions in 2020.

Basal Cell Carcinoma is a skin cancer and is the most common cancer worldwide, with approximately two million new cases diagnosed every year in the U.S. alone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT